$215 Million is the total value of New Leaf Venture Partners, L.L.C.'s 16 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DCPH | New | DECIPHERA THERAPEUTICS INC | $77,938,000 | – | 4,104,140 | +100.0% | 36.17% | – |
| IRTC | Buy | IRHYTHM TECHNOLOGIES INC | $36,510,000 | +29.1% | 703,741 | +5.7% | 16.94% | -14.7% |
| EDGE | EDGE THERAPEUTICS INC | $25,160,000 | +4.6% | 2,344,868 | 0.0% | 11.68% | -30.9% | |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $14,322,000 | -10.6% | 852,497 | -10.5% | 6.65% | -40.9% |
| WVE | WAVE LIFE SCIENCES LTD | $14,317,000 | +16.9% | 658,259 | 0.0% | 6.64% | -22.8% | |
| DMTX | DIMENSION THERAPEUTICS INC | $12,356,000 | +313.8% | 2,059,283 | 0.0% | 5.73% | +173.4% | |
| CRSP | CRISPR THERAPEUTICS AGnamen ak | $9,431,000 | +11.6% | 527,730 | 0.0% | 4.38% | -26.3% | |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $8,543,000 | +24.5% | 2,340,673 | -24.3% | 3.96% | -17.7% |
| SRRA | Buy | SIERRA ONCOLOGY INC | $4,337,000 | +35.1% | 2,798,224 | +2.0% | 2.01% | -10.8% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $2,796,000 | -48.3% | 44,872 | -33.9% | 1.30% | -65.8% |
| OBSV | Buy | OBSEVA SA | $2,119,000 | +7.7% | 260,301 | +13.1% | 0.98% | -28.9% |
| ALDR | ALDER BIOPHARMACUTICALS INC | $2,099,000 | +7.0% | 171,364 | 0.0% | 0.97% | -29.3% | |
| TRILLIUM THERAPEUTICS INC | $2,081,000 | +17.0% | 404,159 | 0.0% | 0.97% | -22.7% | ||
| DERM | DERMIRA INC | $1,650,000 | -7.4% | 61,109 | 0.0% | 0.77% | -38.8% | |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $1,468,000 | – | 250,000 | +100.0% | 0.68% | – |
| OTIC | OTONOMY INC | $357,000 | -82.8% | 109,825 | 0.0% | 0.17% | -88.6% | |
| VSAR | Exit | VERSARTIS INC | $0 | – | -1,448,296 | -100.0% | -17.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 27 | Q1 2024 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| ARVINAS INC | 24 | Q2 2024 | 46.6% |
| CRINETICS PHARMACEUTICALS INC | 24 | Q2 2024 | 11.4% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ALECTOR INC | 22 | Q2 2024 | 4.6% |
| X4 PHARMACEUTICALS INC | 21 | Q2 2024 | 1.1% |
| HARPOON THERAPEUTICS INC | 20 | Q4 2023 | 20.0% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-20 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.